Actively Recruiting
Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
Led by Tongji Hospital · Updated on 2024-12-30
50
Participants Needed
1
Research Sites
184 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, observational, single-center study. The purpose of this study is to evaluate the efficacy of circulating tumor mitochondrial DNA (ct-mtDNA) in plasma as a biomarker for minimal residual disease (MRD) assessment and recurrence monitoring in patients with hepatocellular carcinoma.
CONDITIONS
Official Title
Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with hepatocellular carcinoma (HCC)
- Diagnosis of HCC according to American or European liver disease guidelines
- At least one measurable lesion based on RECIST v1.1 or mRESIST criteria
- Expected survival time of 12 weeks or more
- Signed informed consent and ability to follow study procedures
You will not qualify if you...
- Patients with other active tumors or severe complications
- Insufficient tumor tissue for MRD detection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tongji Hospital
Wuhan, Hubei, China, 430030
Actively Recruiting
Research Team
Z
Ze-yang Ding, M.D.
CONTACT
H
Han Gao
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here